Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Anti-GPC3-scFvGC33-CAR autologous T Lymphocytes |
Synonyms | |
Therapy Description |
Anti-GPC3-scFvGC33-CAR are autologous T-cells that have been engineered to express a chimeric antigen receptor (CAR) based on an antibody (GC33) that targets GPC3, which may induce lysis of GPC3-expressing tumor cells (NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Anti-GPC3-scFvGC33-CAR autologous T Lymphocytes | GAP T cells | Anti-GPC3-scFvGC33-CAR are autologous T-cells that have been engineered to express a chimeric antigen receptor (CAR) based on an antibody (GC33) that targets GPC3, which may induce lysis of GPC3-expressing tumor cells (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02932956 | Phase I | Cyclophosphamide + Fludarabine Anti-GPC3-scFvGC33-CAR autologous T Lymphocytes | Glypican 3-specific Chimeric Antigen Receptor Expressed in T Cells for Patients With Pediatric Solid Tumors (GAP) (GAP) | Active, not recruiting | USA | 0 |